Endostatin neoadjuvant gene therapy extends survival in an orthotopic metastatic mouse model of renal cell carcinoma
Authors:
- Karen Barbosa ChavesKCKaren Barbosa Chaves
- Roger ChammasRCRoger Chammas
- Nestor SchorNSNestor Schor
- Maria Helena BelliniMBMaria Helena Bellini
- 1 June 2012
- journal article
- research article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 66 (4) , 237-241
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Endostatin‐ and interleukin‐2‐expressing retroviral bicistronic vector for gene therapy of metastatic renal cell carcinomaThe Journal of Gene Medicine, 2011
- Template‐based lymphadenectomy in urothelial carcinoma of the upper urinary tract: Impact on patient survivalInternational Journal of Urology, 2010
- Endostatin gene therapy enhances the efficacy of IL-2 in suppressing metastatic renal cell carcinoma in miceCancer Immunology, Immunotherapy, 2010
- Neoadjuvant targeted therapies in renal cell carcinomaNature Reviews Urology, 2010
- Metastatic Renal Cell Carcinoma: Recent Advances in the Targeted Therapy EraEuropean Urology, 2009
- Complete Histologic Remission after Sunitinib Neoadjuvant Therapy in T3b Renal Cell CarcinomaEuropean Urology, 2009
- Laparoscopic right donor nephrectomyBJU International, 2009
- Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigmBJU International, 2008
- Anti‐tumor effect of endostatin mediated by retroviral gene transfer in mice bearing renal cell carcinomaThe FASEB Journal, 2007
- RENAL CELL CARCINOMA 2005: NEW FRONTIERS IN STAGING, PROGNOSTICATION AND TARGETED MOLECULAR THERAPYJournal of Urology, 2005